Navigation Links
Brilliant S+

ProductsBrilliant S+
Company Vitatron B.V.
Item Brilliant S+
Features Two optimally spaced atrial rings ensure reliable P-wave sensing while rejecting far-field signals. The unique lead body design of 9F allows easier passage and positioning. The special designed flexible connectors and small bifurcation sleeve facilitate wrapping around the pacemaker. The steroid eluting electrode provides lower acute and chronic pacing thresholds allowing low pacing output settings. Tip - center atrial rings: 15.5 cm.
Description The Vitatron Brilliant S+ lead series are endocardial leads designed for the Vitatron VDD pacemaker systems offering optimal atrial sensing, superior handling and excellent pacing characteristics.
Info Vitatron B.V.
Customer Service: +31 (0)26 376 7777
Web site: http://www.vitatron.com/

Related medicine products :

1. Impulse II
2. Impulse 3002 Imaging Table (With 2 Speed, Multi-directional Top Slide)
TAG: Brilliant
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6FDAs Woodcock Discusses Pain Management and Drug Safety in Nov 26 2009 Issue of The New England Journal of Medicine 62164 1Biological H1N1 Vaccines 3A Too Little Too Late 14981 1Biological H1N1 Vaccines 3A Too Little Too Late 14981 2Biological H1N1 Vaccines 3A Too Little Too Late 14981 3Biological H1N1 Vaccines 3A Too Little Too Late 14981 4News brief 3A Long term testicular cancer survivors at high risk for neurological side effects 62160 1